This is the authors' abstract. We don't add key points for this paper.
Adverse-risk acute myeloid leukemia (AML) is one of the most life-threatening hematologic malignancies in adults [ 1 ], and allogeneic stem cell transplantation (allo-HSCT) is the standard consolidation therapy after achieving complete remission (CR) [ 2 ]. However, the incidence of AML increases with advancing age, with a median age at diagnosis ranging from 65 to 72 years [ 3 ]. Therefore, how to optimize the transplant strategies in elderly AML patients is crucial, particularly regarding donor selection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: